ArticleSurgical endoscopy2026
Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancreatic cancer following neoadjuvant chemotherapy.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of minimally invasive surgery (MIS) in advanced pancreatic ductal adenocarcinoma (PDAC) remains controversial, particularly after neoadjuvant chemotherapy. Most previous studies have excluded such patients, and evidence supporting MIS in this context is limited. We evaluated the safety, technical feasibility, and oncologic outcomes of minimally invasive distal pancreatectomy (MIDP) following neoadjuvant chemotherapy in patients with advanced pancreatic cancer.
methodsWe retrospectively reviewed 105 patients who underwent distal pancreatectomy with splenectomy for advanced PDAC following neoadjuvant chemotherapy at a single institution between January 2005 and August 2024. Patients were categorized into open (ODP, n = 37) and minimally invasive (MIDP, n = 68) groups. Perioperative outcomes, pathologic features, and long-term survival were compared before and after propensity score matching. Subgroup and multivariable analyses were performed.
resultsMIDP was associated with significantly lower estimated blood loss compared with ODP (166.8 vs. 269.7 mL, p = 0.020), and no patient in the MIDP group required intraoperative transfusion. Other perioperative outcomes, including operation time, postoperative morbidity, and length of hospital stay, were comparable between groups. R0 resection rates, lymph node yield, and pathologic staging did not differ significantly. Long-term disease-free and overall survival were similar between groups, including in patients who received FOLFIRINOX-based neoadjuvant and adjuvant chemotherapy. After propensity score matching, survival outcomes remained comparable. Multivariable analysis identified estimated blood loss and N2 nodal status as independent predictors of recurrence, while N2 nodal status was the only independent predictor of overall survival. The surgical approach was not associated with oncologic outcomes.
conclusionsMinimally invasive distal pancreatectomy is a safe and oncologically sound option for selected patients with advanced PDAC after neoadjuvant chemotherapy. With careful patient selection, MIS may be effectively applied even in technically challenging cases.
Indexed as
Identifiers
41545569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.